TP53 and cancer: This analysis was supported by high frequency of TP53 mutations in gastric adenocarcinomas [18, 19] and the increasing amount of pre-clinical and experimental data, which support a major role of the tumor suppressor gene in orchestrating the glycolytic capability of cancer cells [15, 17].